Navigation Links
NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology
Date:11/28/2007

HUBBARD, Ohio, Nov. 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company announces that the company has submitted international patent applications for BioNanoChannel(TM) and Hydrogen Bioreactor technology protection for China, India, Brazil, and the EU (European Union). These filings are necessary prior to the anticipated global roll-out of the company's BioNanoChannel(TM) rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix's ongoing Hydrogen Bioreactor development.

Chris Novak, NanoLogix Director of IP stated: "The strength and improved focus of the new foreign cases arose from significant improvements to the originally filed provisional patent applications. We at NanoLogix are very excited about the potential for enhancing the patent protection for these new technologies."

According to Bret Barnhizer, NanoLogix President and CEO, "This is a step forward for the company in its plans for technological and business development and sets the stage for one of our corporate goals of pursuing licensing opportunities for use of our products internationally. These applications aid us by ensuring that NanoLogix strengthens their control over the intellectual property rights to the technology."

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and 36 Patents Pending for bioreactor-based Hydrogen Production, revolutionary rapid medical testing technologies, potential treatments for sepsis and cancer (via apoptosis), and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail: Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alvarado Hospital Files Countersuit Against Blue Shield
2. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
3. Pharsight Files Application for Nasdaq Capital Market Listing
4. Gentiva(R) Health Services Files Universal Shelf Registration Statement
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. CIGNA Behavioral Health Offers Members Online Provider Profiles
7. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
8. RxElite Files Registration Statement with Securities and Exchange Commission
9. Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma
10. Mach One Corporation Files its Form SB-2 with the SEC
11. CryoCath files patent infringement lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® XT55 Isolated ... beverages by helping beverage manufacturers more effectively manage protein costs. “Soy protein has ... as well as more stable pricing over time. Now it’s even more relevant ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader in ... a new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC ... signs of aging, and minimize the appearance of pores – all with minimal ...
(Date:4/25/2017)... ... 25, 2017 , ... Coalition Duchenne, a ... muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on positive ... trial in Duchenne announced today. , Coalition Duchenne funded studies carried out ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WARSAW, Ind. , April 20, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Health Care Conference at the InterContinental Hotel in ... 2017.  Zimmer Biomet will present at 11:20 a.m. Eastern ... can be accessed via Zimmer Biomet,s Investor Relations website ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
Breaking Medicine Technology: